Yazar "Disli, Zeliha Korkmaz" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Comparison of tocilizumab and intravenous immunoglobulin treatment in intensive care unit patients with COVID-19 who developed cytokine storm: A single-center retrospective study
    (Bayrakol Medical Publisher, 2024) Kalkan, Serkan; Demircan, Selcuk; Disli, Zeliha Korkmaz; Duzenci, Deccane; Memisoglu, Funda; Yalcinsoy, Murat; Bicakcioglu, Murat
    Aim: Coronavirus disease 2019 (COVID-19) may trigger a severe inflammatory response. In the present study, the effects of tocilizumab and intravenous immunoglobulin (IVIG) on mortality in COVID-19 patients with cytokine storms were examined and compared. Material and Methods: This retrospective study included all COVID-19 patients who were diagnosed and followed in the intensive care unit between April 2020 and May 2022. The patients were divided into two groups depending on whether they were receiving IVIG or tocilizumab treatment. In addition to the patients' demographic information, the 28-day mortality was recorded. Their PaO2/FiO2 ratio, CRP, procalcitonin, lymphocyte, ferritin, and D-dimer levels were also recorded before drug administration and on the first day, third day, and first week following the drug administration. Results: Of the 73 patients included in this study, 43 (59%) received tocilizumab (Group T), while 30 (41%) received IVIG treatment (Group IVIG). No significant statistical differences were detected between the groups in terms of demographic data, pre-drug inflammatory parameters, improvement in PaO2/FiO2 ratios, and 28-day mortality. The rate of change in CRP levels was significantly higher in Group T than in Group IVIG on day 3 (p=0.010) and in the first week (p=0.001). The improvement in ferritin levels in the first week was significantly higher in Group T (p=0.018). Discussion: No significant difference was detected between the effects of IVIG and tocilizumab on mortality in COVID-19 patients with cytokine storm. However, tocilizumab suppressed inflammation more strongly than IVIG.
  • Küçük Resim Yok
    Öğe
    The effects of thiamine pyrophosphate on propofol-induced oxidative liver injury and effect on dysfunction
    (Aepress Sro, 2022) Delen, Leman Acun; Disli, Zeliha Korkmaz; Tas, Hakan G.; Kuyrukluyildiz, Ufuk; Yazici, Gulce N.; Suleyman, Bahadir; Kuzucu, Mehmet
    Propofol may cause an increase in reactive oxygen species in the body. In this study, we tested the effect of antioxidant thiamine pyrophosphate (TPP) on propofol-induced liver damage. The eighteen rats were split into three groups: HG, healthy; PP, propofol-treated (50 mg/kg) and PT, treated with propofol (50 mg/kg) and TPP (25 mg/kg). Total glutathione (tGSH), total oxidant (TOS), and total antioxidant (TAS) levels were tested together with aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) and malondialdehyde (MDA). Histopathological examination of the tissues was performed. We have found that levels of MDA, TOS, ALT, AST, and LDH were all higher in PP group than in HG and PT groups (p < 0.05). In PP group, the TAS and tGSH levels were statistically substantially lower. The PT for oxidants levels showed a statistically significant reduction. In PT group, the levels of antioxidants were found to be considerably higher. The epitheliums, glands, and vascular structures of the PTs were histologically close to normal. By boosting antioxidants, TPP may help to reduce propofol-induced liver damage.
  • Küçük Resim Yok
    Öğe
    The Molecular Mechanism of the Effect of Carvacrol on Desflurane Inhalation-Induced Liver Damage in Rats
    (Colegio Farmaceuticos Provincia De Buenos Aires, 2022) Disli, Zeliha Korkmaz; Delen, Leman Acun; Tas, Hakan Gokalp; Kuyrukluyildiz, Ufuk; Disli, Olcay Murat; Yazici, Gulce Naz; Coban, Abdulkadir
    The metabolite of desflurane has been linked to hepatotoxicity. Carvacrol possesses antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, and spasmolytic properties, according to research. Our goal is to demonstrate that carvacrol protects rats' livers against repeated doses of desflurane. Healthy (HG), desflurane (DS), and carvacrol + desflurane treatment (CDS) groups were formed from 18 albino male Wistar rats. A single dosage of carvacrol and 6% desflurane was given for 2 h on the 0th and 8th days. In the CDS group, the ALT and AST, MDA, TOS, NF-xB, TNF-alpha IL1 beta levels were lower compared to the DS group (p < 0.001). The tGSH,TAS levels were found to be higher in the CDS group compared to the DS group (p < 0.001). It was determined that the mean degeneration level, Kupffer cell activation and PMNL infiltration were found to be lower compared to the DS group (p < 0.05).We confirmed that carvacol can be used in the treatment of desflurane-related liver injury.